{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+B-cell+Non-Hodgkin+Lymphoma&page=44", "query": { "condition": "Refractory B-cell Non-Hodgkin Lymphoma", "page": 44 }, "page_size": 10 }, "pagination": { "page": 44, "page_size": 10, "total_count": 1227, "total_pages": 123, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+B-cell+Non-Hodgkin+Lymphoma&page=45&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+B-cell+Non-Hodgkin+Lymphoma&page=43&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-19T15:26:54.145Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06742996", "title": "A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Mantle Cell Lymphoma", "B Cell Lymphoma" ], "interventions": [ { "name": "Sonrotoclax", "type": "DRUG" }, { "name": "Zanubrutinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeOne Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "2025-03-05", "completion_date": "2032-03-30", "has_results": false, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-19T15:26:54.145Z", "location_count": 41, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Fresno, California + 34 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fresno", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT06742996" }, { "nct_id": "NCT05794958", "title": "Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Hodgkin Lymphoma", "Large B-cell Lymphoma" ], "interventions": [ { "name": "Axicabtagene Ciloleucel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2023-05-23", "completion_date": "2038-04-01", "has_results": false, "last_update_posted_date": "2025-09-23", "last_synced_at": "2026-10-19T15:26:54.145Z", "location_count": 1, "location_summary": "Palo Alto, California", "locations": [ { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05794958" }, { "nct_id": "NCT00079443", "title": "FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "romidepsin", "type": "DRUG" }, { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2004-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-07-01", "last_synced_at": "2026-10-19T15:26:54.145Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00079443" }, { "nct_id": "NCT03418038", "title": "Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clonal Cytopenia of Undetermined Significance", "High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements", "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Hodgkin Lymphoma", "Recurrent Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory Lymphoma", "Chronic Myelomonocytic Leukemia" ], "interventions": [ { "name": "Ascorbic Acid", "type": "DIETARY_SUPPLEMENT" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Placebo Administration", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Decitabine", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Core Biopsy", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Echocardiography", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Central Venous Cannula Insertion", "type": "PROCEDURE" }, { "name": "Portacath Placement", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Decitabine and Cedazuridine", "type": "DRUG" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "DRUG", "OTHER", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2018-03-23", "completion_date": "2033-11-02", "has_results": false, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-19T15:26:54.145Z", "location_count": 4, "location_summary": "Mankato, Minnesota • Rochester, Minnesota • Eau Claire, Wisconsin + 1 more", "locations": [ { "city": "Mankato", "state": "Minnesota" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Eau Claire", "state": "Wisconsin" }, { "city": "La Crosse", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT03418038" }, { "nct_id": "NCT04029038", "title": "Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "CD19 Positive", "CD22 Positive", "Minimal Residual Disease", "Progressive Disease", "Recurrent B Acute Lymphoblastic Leukemia", "Recurrent Chronic Lymphocytic Leukemia", "Recurrent Non-Hodgkin Lymphoma", "Refractory B Acute Lymphoblastic Leukemia", "Refractory Chronic Lymphocytic Leukemia", "Refractory Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Autologous CD19/CD22 Chimeric Antigen Receptor T-cells", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "70 Years", "sex": "ALL", "summary": "6 Months to 70 Years" }, "enrollment_count": 0, "start_date": "2019-05-15", "completion_date": "2022-11-16", "has_results": false, "last_update_posted_date": "2023-08-21", "last_synced_at": "2026-10-19T15:26:54.145Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04029038" }, { "nct_id": "NCT04231747", "title": "A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma Non-Hodgkin", "Agressive Lymphoma", "Diffuse-large B-cell Lymphoma (DLBCL)" ], "interventions": [ { "name": "CC-97540", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Juno Therapeutics, a Subsidiary of Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2020-05-21", "completion_date": "2024-02-01", "has_results": false, "last_update_posted_date": "2024-05-20", "last_synced_at": "2026-10-19T15:26:54.145Z", "location_count": 11, "location_summary": "Birmingham, Alabama • Atlanta, Georgia • Boston, Massachusetts + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04231747" }, { "nct_id": "NCT02568683", "title": "Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Entospletinib", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2016-02-11", "completion_date": "2017-06-22", "has_results": true, "last_update_posted_date": "2019-04-17", "last_synced_at": "2026-10-19T15:26:54.145Z", "location_count": 2, "location_summary": "Hattiesburg, Mississippi • Charleston, South Carolina", "locations": [ { "city": "Hattiesburg", "state": "Mississippi" }, { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02568683" }, { "nct_id": "NCT02219737", "title": "Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "CD20 Positive", "Recurrent Diffuse Large B-Cell Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2014-09-12", "completion_date": "2017-05-11", "has_results": false, "last_update_posted_date": "2018-01-26", "last_synced_at": "2026-10-19T15:26:54.145Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02219737" }, { "nct_id": "NCT05618366", "title": "Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma, Non-Hodgkin", "Diffuse Large B Cell Lymphoma", "Follicular Lymphoma" ], "interventions": [ { "name": "Venetoclax", "type": "DRUG" }, { "name": "Tazemetostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2023-06-07", "completion_date": "2026-02-27", "has_results": false, "last_update_posted_date": "2026-04-02", "last_synced_at": "2026-10-19T15:26:54.145Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05618366" }, { "nct_id": "NCT01925131", "title": "S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Leukemias of Ambiguous Lineage", "B-cell Adult Acute Lymphoblastic Leukemia", "Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Burkitt Lymphoma" ], "interventions": [ { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "inotuzumab ozogamicin", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2014-06-13", "completion_date": "2023-01-01", "has_results": true, "last_update_posted_date": "2023-05-03", "last_synced_at": "2026-10-19T15:26:54.145Z", "location_count": 5, "location_summary": "Duarte, California • Palo Alto, California • Rochester, New York + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Rochester", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01925131" } ] }